1. FDA adding HF warnings to labels of alogliptin, saxagliptin

   News item 16 April 2016 Pages: 1 - 1

2. Febuxostat may increase risk of heart failure

   News item 16 April 2016 Pages: 2 - 2

3. HBV reactivation with BCR-ABL TKIs: new safety information

   Correspondence 16 April 2016 Pages: 3 - 3

4. Labelling amended following ibrutinib-related hepatotoxicity

   News item 16 April 2016 Pages: 4 - 4

5. Pertuzumab linked to Stevens-Johnson syndrome?

   News item 16 April 2016 Pages: 5 - 5

6. PROTECT improves benefit-risk monitoring of medicines in EU

   News item 16 April 2016 Pages: 6 - 6

7. Xgeva information updated in Australia

   News item 16 April 2016 Pages: 7 - 7

8. Corticosteroids affect growth patterns in boys with DMD

   Clinical study 16 April 2016 Pages: 8 - 8

9. Drug advice influences physicians' prescribing habits in pregnancy

   Clinical study 16 April 2016 Pages: 9 - 9

10. Evolocumab safe in patients with statin intolerance

    Clinical study 16 April 2016 Pages: 10 - 10

11. Ribavirin increases AEs in patients receiving ledipasvir/sofosbuvir

    Clinical study 16 April 2016 Pages: 11 - 11

12. TNF inhibitors associated with glioblastoma multiforme

    Clinical study 16 April 2016 Pages: 12 - 12

13. Acetazolamide

    Case report 16 April 2016 Pages: 13 - 13

14. Adalimumab/infliximab

    Case report 16 April 2016 Pages: 14 - 14

15. Afatinib

    Case report 16 April 2016 Pages: 15 - 15

16. Alitretinoin

    Case report 16 April 2016 Pages: 16 - 16

17. Amfetamine abuse

    Case report 16 April 2016 Pages: 17 - 17

18. Amikacin/cefoxitin/clarithromycin/linezolid

    Case report 16 April 2016 Pages: 18 - 18

19. Amoxicillin

    Case report 16 April 2016 Pages: 19 - 19

20. Amoxicillin/clavulanic acid/ceftazidime

    Case report 16 April 2016 Pages: 20 - 20

21. Anakinra

    Case report 16 April 2016 Pages: 21 - 21

22. Antineoplastic agents/aspirin/low molecular weight heparins

    Case report 16 April 2016 Pages: 22 - 22

23. Antineoplastics

    Case report 16 April 2016 Pages: 23 - 23

24. Antineoplastics

    Case report 16 April 2016 Pages: 24 - 24

25. Antineoplastics

    Case report 16 April 2016 Pages: 25 - 25

26. Antineoplastics

    Case report 16 April 2016 Pages: 26 - 26

27. Antineoplastics

    Case report 16 April 2016 Pages: 27 - 27

28. Antineoplastics/doxorubicin/methylprednisolone

    Case report 16 April 2016 Pages: 28 - 28

29. Antipsychotics

    Case report 16 April 2016 Pages: 29 - 29

30. Antipsychotics

    Case report 16 April 2016 Pages: 30 - 30

31. Antiretroviral therapy/vinblastine interaction

    Case report 16 April 2016 Pages: 31 - 31

32. Antituberculars

    Case report 16 April 2016 Pages: 32 - 32

33. Antivirals

    Case report 16 April 2016 Pages: 33 - 33

34. Apixaban/rivaroxaban

    Case report 16 April 2016 Pages: 34 - 34

35. Aripiprazole/fluoxetine

    Case report 16 April 2016 Pages: 35 - 35

36. Asparaginase

    Case report 16 April 2016 Pages: 36 - 36

37. Aspirin/clopidogrel

    Case report 16 April 2016 Pages: 37 - 37

38. Azithromycin/colchicine

    Case report 16 April 2016 Pages: 38 - 38

39. Baclofen

    Case report 16 April 2016 Pages: 39 - 39

40. Baclofen

    Case report 16 April 2016 Pages: 40 - 40

41. BCG

    Case report 16 April 2016 Pages: 41 - 41

42. Belimumab withdrawal

    Case report 16 April 2016 Pages: 42 - 42

43. Betamethasone/dexchlorpheniramine

    Case report 16 April 2016 Pages: 43 - 43

44. Bevacizumab

    Case report 16 April 2016 Pages: 44 - 44

45. Bleomycin/cisplatin/etoposide

    Case report 16 April 2016 Pages: 45 - 45

46. Bleomycin/oxaliplatin/rituximab

    Case report 16 April 2016 Pages: 46 - 46

47. Bumetanide/chlorothiazide

    Case report 16 April 2016 Pages: 47 - 47

48. Bupivacaine

    Case report 16 April 2016 Pages: 48 - 48

49. Canagliflozin

    Case report 16 April 2016 Pages: 49 - 49

50. Canakinumab

    Case report 16 April 2016 Pages: 50 - 50